Brokerages Set Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) Price Target at $29.00

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) has received a consensus rating of “Moderate Buy” from the eight analysts that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $29.00.

Several equities research analysts recently issued reports on the company. Piper Sandler upped their price target on Kestra Medical Technologies from $27.00 to $30.00 and gave the stock an “overweight” rating in a report on Friday, December 12th. Stifel Nicolaus set a $30.00 price objective on Kestra Medical Technologies in a research note on Friday, December 12th. Wells Fargo & Company lifted their price objective on shares of Kestra Medical Technologies from $27.00 to $28.00 and gave the stock an “overweight” rating in a report on Friday, December 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Kestra Medical Technologies in a research note on Wednesday, December 24th. Finally, The Goldman Sachs Group set a $24.00 price target on shares of Kestra Medical Technologies in a research report on Friday, January 16th.

Key Kestra Medical Technologies News

Here are the key news stories impacting Kestra Medical Technologies this week:

• Positive Sentiment: Revenue growth and raised guidance: Q3 revenue was $24.55M, up 62.7% year‑over‑year, and management raised FY2026 revenue guidance to $93M — evidence of accelerating sales and market expansion. GlobeNewswire Release
• Positive Sentiment: Analyst support: BTIG reaffirmed a “buy” and set a $32 price target (~60%+ upside from current levels), which can provide investor confidence and buying interest. Benzinga
• Positive Sentiment: Management commentary highlights expansion and margin progress on the earnings call, which supports the upbeat guidance and growth narrative. Seeking Alpha Transcript
• Neutral Sentiment: Full call/transcript and press materials are available for deeper due diligence — useful for investors who want to parse cadence, customer wins and margin drivers. Yahoo Finance Transcript
• Negative Sentiment: EPS miss and continued unprofitability: Reported EPS of ($0.61) missed the consensus ($0.60) by $0.01; the company still shows negative net margin (~‑171.9%) and negative ROE, underscoring that growth is not yet translating into profitability. MarketBeat Earnings Summary
• Negative Sentiment: Market reaction/technicals: Shares are trading below both the 50‑ and 200‑day moving averages and volume is well above average, indicating sellers dominated today as investors digested the mixed report. (Balance sheet liquidity is solid, but profitability concerns and the EPS miss likely drove the sell‑off.)

Insider Activity

In other Kestra Medical Technologies news, insider Traci S. Umberger sold 10,500 shares of Kestra Medical Technologies stock in a transaction that occurred on Monday, December 29th. The shares were sold at an average price of $26.69, for a total transaction of $280,245.00. Following the transaction, the insider owned 136,633 shares of the company’s stock, valued at $3,646,734.77. This trade represents a 7.14% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Brian Daniel Webster sold 15,000 shares of the business’s stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $25.60, for a total value of $384,000.00. Following the completion of the transaction, the insider owned 379,786 shares in the company, valued at $9,722,521.60. The trade was a 3.80% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 55,500 shares of company stock valued at $1,405,095. Company insiders own 3.60% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Russell Investments Group Ltd. raised its stake in shares of Kestra Medical Technologies by 43.5% during the 4th quarter. Russell Investments Group Ltd. now owns 1,563 shares of the company’s stock worth $41,000 after purchasing an additional 474 shares during the period. Brown Brothers Harriman & Co. grew its position in Kestra Medical Technologies by 26.8% during the third quarter. Brown Brothers Harriman & Co. now owns 3,104 shares of the company’s stock valued at $74,000 after buying an additional 656 shares during the period. Rhumbline Advisers increased its holdings in Kestra Medical Technologies by 7.3% during the third quarter. Rhumbline Advisers now owns 12,925 shares of the company’s stock worth $307,000 after buying an additional 874 shares during the last quarter. Farther Finance Advisors LLC bought a new stake in Kestra Medical Technologies in the fourth quarter worth about $31,000. Finally, Police & Firemen s Retirement System of New Jersey boosted its stake in Kestra Medical Technologies by 34.6% in the fourth quarter. Police & Firemen s Retirement System of New Jersey now owns 5,420 shares of the company’s stock valued at $144,000 after acquiring an additional 1,392 shares during the last quarter.

Kestra Medical Technologies Price Performance

Shares of NASDAQ KMTS opened at $19.58 on Monday. The stock has a market cap of $1.14 billion and a price-to-earnings ratio of -4.94. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.47 and a current ratio of 5.47. Kestra Medical Technologies has a fifty-two week low of $13.25 and a fifty-two week high of $30.00. The firm’s 50-day simple moving average is $24.19 and its 200 day simple moving average is $24.53.

Kestra Medical Technologies (NASDAQ:KMTS) last issued its quarterly earnings data on Tuesday, March 17th. The company reported ($0.61) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.01). The company had revenue of $24.55 million for the quarter. Kestra Medical Technologies had a negative return on equity of 74.66% and a negative net margin of 171.87%.Kestra Medical Technologies’s revenue for the quarter was up 62.7% compared to the same quarter last year.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.